Mission, Vision
and Values

Executive
Leadership of
AGC Pharma
Chemicals Europe

AGC Pharma Chemicals is a Global Contract Development and Manufacturing Organization (CDMO), based in Spain and Japan, manufacturing small molecule Active Pharmaceutical Ingredients (APIs) and intermediates

AGC Pharma Chemicals belongs together with AGC Biologics and AGC Agro to the Life Sciences Business of AGC.

AGC Group

Founded in

1907

Employees

55,999

Group Companies

206

companies

FY2021 net sales

€ 12,731

million

The AGC Group is a global business conglomerate with over 206 companies, extending into over 30 countries with net sales of € 12,731 million (Y120 = €1) during 2021.

Under our long-term management strategy, Vision 2030, we aim to create sustainable economic and social value, enhance each business’s competitiveness, and build a solid and long-term stable earnings base. Business Process Excellence is embedded into our organization’s culture.

The group has over 40 years of CDMO experience. Through acquisitions and investments, Life Science has become a strategic pillar, with state-of-the-art innovative Research and Development (R&D) centers in Japan, Europe and the US, and multi-purpose facilities with a broad portfolio of technologies.

AGC Life Science Business

AGC Pharma Chemicals Europe

AGC acquired the former API plant of Boehringer Ingelheim in Malgrat de Mar, Spain. The plant has been operational as AGC Pharma Chemicals Europe, S.L.U. since the 1st March 2019. It is the first FDA registered site in Europe for AGC to help broaden its pharmaceutical CDMO business. Specializing in Process Development, scaling up, and optimization, the new R&D lab has been operational since March 2021 and has tripled capacity.

Our services are based on specialized technologies and complement production facilities that support customer projects. We are committed to the highest levels and cGMP quality standards.

AGC Pharma Chemicals focuses on:

Extensive know-how and experience in ton-scale fluorination
Various hazardous reactions (e.g. cyano, diazo, Cl, reactions)
Ultra-low temperature reactions
High potent substances available
Fully support your projects from early stage to commercial stage compliant with cGMP

AGC Chiba Japan

Established in 1959 on the waterfront industrial park in Ichihara City, Chiba Prefecture, the plant was merged with AGC Inc in January 2009.

We have two cGMP plants supporting clinical phase projects and high-volume commercial phase manufacturing for APIs and Intermediates. Our multi-purpose facility is compatible with diverse processes, with a core structure and gravity-based facility design that guarantees flexibility and high quality.

YTC (Yokohama Technical Center) R&D center in Japan

The AGC Yokohama Technical Center (former Keihin Plant) started operation in 1916 at Tsurumi, Yokohama and was renewed and expanded in 2020. With more than 250 talented scientist, it is the center of global innovation within AGC and includes an R&D area for small molecule CDMO including HAPI handling where a team of 35 chemists supports AGC Pharma Chemicals.

Some of the capabilities:

Develop synthesis route
Analytical R&D
Scale up
Process safety assessment
Optimization
Innovative technologies initiated by our organic synthesis expertise

AGC Wakasa Chemicals

Established in 1998 on the waterfront side in Obama City, Fukui Prefecture, AGC Wakasa Chemical has one cGMP compliant site and also non-GMP sites for Agrochemicals, registered starting materials and raw materials.

AGC Biologics

AGC Biologics provides world-class development and manufacturing services for mammalian and microbial-based therapeutic proteins, messenger RNA (mRNA), plasmid DNA (pDNA), viral vectors, and cell therapies.

From development to clinical trials to full-scale commercialization, our purpose is to bring hope to life by enabling the development and manufacturing of life-changing therapies for patients around the globe.

Our global sites have successfully manufactured 250+ biologics, 400+ batches of GMP viral vectors, and supplied materials for 30+ CGT clinical trials.

Mission

Our Mission is to make people’s lives better by manufacturing and supplying the pharmaceutical industry with high-quality products and reliable services.

Vision

Our Vision is to become a first choice global CDMO and a center of excellence for the manufacture of high-quality products for our customers.

Values

Customer Orientation

Our customer focus and commitment drives us to know our clients, understand their needs and deliver value.

Challenge

We challenge ourselves to deliver better results, achieve our goals, evolve and adapt to obstacles to find solutions.

Operational Excellence

We ensure that our activities and processes are carried out per the highest standards of excellence because we pride ourselves on demonstrating compliance with all applicable regulatory standards while investing in a continuous improvement culture.

Team Excellence

We cooperate to achieve common goals, creating a positive, innovative and continuous learning environment that enables our teams to push for excellence.